Co-provided By

This activity is co-provided by Rush University and PleXus Communications.

Activity Details

0.5 AMA PRA Category 1 Credits
0.5 Contact Hour(s)
Released: September 27, 2017
Expires: September 26, 2018
30 minutes to complete

Target Audience

Healthcare providers who are involved with the treatment of patients with prostate cancer

Learning Objectives

After completing this program, participants should be able to:

  1. Outline how a personalized approach to treatment, as it relates to the genetic landscape of prostate cancer, can impact patient prognosis and treatment selection
  2. Formulate appropriate care plans for patients with advanced prostate cancer based on individual patient disease characteristics, including considerations of the best clinically relevant strategies for combining and sequencing therapies
  3. Evaluate emerging treatment options for advanced prostate cancer based upon individual patient disease characteristics and treatment-related complications


  • Androgen receptor access
  • Next generation AR-targeting agents: Lessons Learned
  • Does the earlier use of chemotherapy or next generation AR targeting agents improve survival?
  • Summary of therapies with survival benefit for mCRPC
  • Novel approaches for prostate cancer: DNA repair and Cancer

Activity Description

The activity agenda has been designed to help clinicians understand best practice approaches to utilizing all the current therapies in advanced prostate cancer to ensure optimal patient outcomes.


Daniel P. Petrylak, MD
Professor of Medicine and Urology
Director, Genitourinary DART
Co-director, Signal Transduction Program
Smilow Cancer Center
Yale University School of Medicine
New Haven, CT

Research Grant: Celgene Corporation
Consultant: Celgene Corporation, Bristol-Myers Squibb (advisory board), Binding Site, Karyopharm Therapeutics, Janssen, Sanofi, and Takeda Pharmaceuticals U.S.A., Inc.

Conflict of Interest Policy/Disclosure Statement

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the healthcare team.

Rush University Medical Center designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

ANCC Credit Designation – Nurses
The maximum number of hours awarded for this CE activity is 0.5 contact hours.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this knowledge based CPE activity (0622-0000-17-039-H01-P) for 0.5 contact hours for pharmacists.

Instructions for Receiving Credit

Participants must complete and submit the online CE evaluation form at the conclusion of the activity and achieve a passing score of 75% or better. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by educational grants from Astellas Scientific and Medical Affairs, Inc. and Medivation Inc., a Pfizer Company, Bayer HealthCare Pharmaceuticals Inc., Clovis Oncology, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Sanofi Genzyme.

Disclaimer Statement / Disclosure of Unlabeled Use

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Rush University, PleXus Communications, and/or the commercial supporters. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Rush University, PleXus Communications and/or the commercial supporters. Rush University’s ANCC accreditation status does not imply endorsement by Rush or ANCC of any commercial products displayed in conjunction with this activity. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Contact Information for Questions About the Activity

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.